Adage Capital Partners Gp, L.L.C. Arcus Biosciences, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $1.29 Million - $2.83 Million	-75,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $3.98 Million - $6.26 Million	-175,000 Reduced 70.0%	75,000 $2.06 Million
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $3.49 Million - $9.14 Million	250,000 New	250,000 $6.19 Million

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.12B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.